Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475675 | 0.90 | TSHR (0.59) | CYP11B1CYP11B2FFAR4GRM5SMN1; SMN2 | |
| SCHEMBL4478047 | 0.89 | GRM5 (0.59) | FFAR4GRM5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4478243 | 0.84 | CYP11B1 (0.60) | CYP11B1CYP11B2RAB9ANPC1TP53 | |
| SCHEMBL12412646 | 0.84 | GRM5 (0.77) | GRM5 | |
| SCHEMBL12830278 | 0.84 | GRM5 (0.58) | FFAR4GRM5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12412147 | 0.84 | GRM5 (0.61) | GRM5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4481536 | 0.83 | CYP11B1 (0.69) | CYP11B1CYP11B2RAB9ANPC1TP53 | |
| SCHEMBL4472388 | 0.82 | RAB9A (0.66) | CYP11B1CYP11B2RAB9ANPC1TP53 | |
| SCHEMBL4492925 | 0.81 | GRM5 (0.63) | CYP11B1CYP11B2RAB9ANPC1TP53 | |
| SCHEMBL4276324 | 0.81 | TAAR1 (0.64) | CYP11B1CYP11B2RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | CYP11B1 3034/4885CYP11B2 2294/4885RAB9A 2534/4885 |
| US-20060173024-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | CYP11B1 3034/4885CYP11B2 2294/4885RAB9A 2534/4885 |
| US-20050148638-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | CYP11B1 3034/4885CYP11B2 2294/4885RAB9A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.